Seeking Alpha

Seeking Alpha Portfolio App for iPad

1,151 people get EW articles and Market Currents by email alert.

Get email alerts on EW »

EW

Edwards Lifesciences Corp

5/21/2013, 3:29 AM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, May 14, 9:33 AM Edwards Lifesciences (EW +2.7%) news roundup: Company authorizes a new $750M buyback program and says it will complete the remainder ($140M) of its previously authorized repurchase program during Q2; CEO Michael Mussallem will purchase $5M worth of shares tomorrow at either Wednesday's closing price or the average closing price for the 10 trading days ending Monday, whichever is higher; CFO Thomas Abate will retire this year. Despite a 5-day, ~5% rally, the shares are still reeling from April 24th's post-earnings dive and subsequent downgrades. Comment! [Healthcare, On the Move]
Wednesday, April 24, 12:44 PM Midday top 10 gainers: RSOL +31%. NOR +27%. BKI +26%. BYD +18%. IRBT +15%. CHCI +14%. RVLT +13%. FXEN +12%. TRQ +12%. LL +12%.
Midday top 10 losers: VOCS -37%. VLTC -24%. EW -23%. UIS -23%. DV -21%. CCCL -15%. MCOX -14%. MEG -14%. SCON -13%. MACK -13%. Comment! [On the Move]
Wednesday, April 24, 9:11 AM Premarket gainers: BKI +26%. PBTH +11%. LL +7%. PSTI +5%.
Losers: VOCS -31%. UIS -20%. EW -19%. RES -13%. AWAY -9%. SCON -9%. JNPR -7%. SVU -7%. PNRA -6%. CREE -6%. Comment! [On the Move]
Wednesday, April 24, 8:14 AM The cuts come fast following Edward Lifesciences' (EW) earnings miss last night: "We no longer have confidence in management executing on the (Sapien) U.S. launch," says RBC, cutting its PT to $72 from $102. "We would not be buyers (at $70)," says Lazard. JPM: "We've cut our price target to $68, but the risks in our view still point to the downside ... growth is likely to decelerate further in 2014 and even more so in 2015." Read what all of these analysts had to say on the earnings call. Shares -17% premarket. Comment! [Healthcare, On the Move]
Tuesday, April 23, 4:11 PM Edwards Lifesciences (EW): Q1 EPS of $0.72 misses by $0.04. Revenue of $496.7M (+8.2% Y/Y) misses by $21.99M. Shares -10.6% AH. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
Tuesday, April 23, 12:10 AM Notable earnings after Tuesday’s close: AAPL, ACC, AMGN, AWAY, BCR, BRCM, CREE, DV, EW, FBC, FTI, HA, HBI, HLIT, HTS, IRBT, ITC, JNPR, LIFE, NBR, NFX, NSC, OI, OII, OMI, PACB, PLCM, PNRA, RFMD, RHI, T, UIS, USNA, VMW, WRB, YUM, ZIXI Comment! [Earnings]
Monday, April 22, 5:35 PM Notable earnings after Tuesday’s close: AAPL, ACC, AMGN, AWAY, BCR, BRCM, CREE, DV, EW, FBC, FTI, HA, HBI, HLIT, HTS, IRBT, ITC, JNPR, LIFE, NBR, NFX, NSC, OI, OII, OMI, PACB, PLCM, PNRA, RFMD, RHI, T, UIS, USNA, VMW, WRB, YUM, ZIXI Comment! [Earnings]
Tuesday, February 5, 2:56 PM Jefferies analyst Raj Denhoy comes out defending Edwards Lifesciences (EW -6.5%) on weakness today, reiterating his Buy rating and upping his price target to $114 from $100. Denhoy says its quarter was solid, and the higher price target is due to strong US Sapien transcatheter heart valve sales, which are tracking ahead of expectations. Comment! [Healthcare, Earnings, On the Move]
Monday, February 4, 5:49 PM More on Edwards Lifesciences (EW): Q4 beats on both EPS and revenue as total sales jump 18% Y/Y. Net profit also soared by 44% versus the prior year period as revenue improved across the medical-device company's segments - led by sales of transcatheter heart valves - and the period was also boosted by a tax benefit. Looking forward, the company expects to benefit from October's FDA decision to expand the approved use of its Sapien device to include high-risk surgery patients, and the company is investing heavily into that expansion. Shares +0.5% AH. Comment! [Healthcare, Earnings]
Monday, February 4, 4:06 PM Edwards Lifesciences (EW): Q4 EPS of $0.9 beats by $0.13. Revenue of $510.5M (+18.7% Y/Y) beats by $11.04M. Shares +1% AH. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
Monday, February 4, 12:10 AM Notable earnings after Monday’s close: ACLS, APC, APKT, ARRY, BIDU, EW, GGP, GILD, HI, HIG, HOLX, LEG, LIFE, MDU, MKL, SIMO, SWI, YUM Comment! [Earnings]
Sunday, February 3, 5:35 PM Notable earnings after Monday’s close: ACLS, APC, APKT, ARRY, BIDU, EW, GGP, GILD, HI, HIG, HOLX, LEG, LIFE, MDU, MKL, SIMO, SWI, YUM Comment! [Earnings]
Monday, November 19, 2012, 3:56 PM As the appetite for waging war against Obamacare wanes, smaller fixes are starting to come into the limelight, and are becoming increasingly more realistic, as long as every minor issue doesn’t blow up into a full-scale battle. One small fight is now being picked by medical device companies, who are trying to use the debate to get ObamaCare's tax on medical devices repealed, and it appears that some Democrats may support that initiative. Comment! [Healthcare]
Monday, November 19, 2012, 2:23 PM St. Jude Medical (STJ +2%) says its received European approval for its Portico heart valve replacement device. The approval gives STJ access to a burgeoning market for the devices, and the news gives a much-needed lift to the stock after a string of negative headlines in recent months has driven the stock down near 52-week lows. Since October alone, STJ has shaved nearly 17% off its market cap. Comment! [Healthcare, On the Move]
Tuesday, November 13, 2012, 3:18 PM Edwards Lifesciences(EW +1.7%) says a U.S. Appeals Court has affirmed a 2010 federal jury decision that Medtronic (MDT +0.3%) is infringing the company's U.S. Andersen transcatheter heart valve patent, as well as an initial payment award to EW of $74M. The court also ordered the trial court to reconsider EW's request for a permanent injunction that would prohibit the sale of Medtronic's CoreValve system in the U.S. Comment! [Healthcare]
Friday, October 19, 2012, 4:19 PM More on Edwards Lifesciences (EW): Q3 beats on a per share basis but comes up short on revenue as sales growth in its transcatheter heart valves ran below expectations. Looking forward, the company says it expects a strong close to the year with today's FDA approval of expanded indications for SAPIEN, which will allow it to serve many more patients. Comment! [Healthcare, Earnings]